Page 76 - Read Online

Page 14 of 14 Jayachandran et al. Hepatoma Res 2020;6:8 I http://dx.doi.org/10.20517/2394-5079.2019.35

mediated by cyclin4-dependent kinase-1/STAT3 pathway. Diagnostics (Basel) 2019;9.
112. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol 1992;80:235-41.
113. Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism
for neoplasia in hemochromatosis. Ann N Y Acad Sci 1988;526:301-9.
114. Cozma A, Fodor A, Vulturar R, Sitar-Tăut AV, Orăşan OH, et al. DNA methylation and micro-RNAs: the most recent and relevant
biomarkers in the early diagnosis of hepatocellular carcinoma. Medicina (Kaunas) 2019;55.
115. Lehmann U, Wingen LU, Brakensiek K, Wedemeyer H, Becker T, et al. Epigenetic defects of hepatocellular carcinoma are already
found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet 2007;16:1335-42.
116. Adams P, Altes A, Brissot P, Butzeck B, Cabantchik I, et al. Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr
(C282Y/C282Y) homozygous genotype. Hepatol Int 2018;12:83-6.
117. Loréal O, Cavey T, Robin F, Kenawi M, Guggenbuhl P, et al. Iron as a therapeutic target in HFE-related hemochromatosis: usual and
novel aspects. Pharmaceuticals (Basel) 2018;11.
118. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of
iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671-779.
119. Tauchenová L, Křížová B, Kubánek M, Fraňková S, Melenovský V, et al. Successful treatment of iron-overload cardiomyopathy in
hereditary hemochromatosis with deferoxamine and deferiprone. Can J Cardiol 2016;32:1574.e1-e3.
120. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that
overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103:14901-6.
121. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective
antiproliferative agents. Blood 1995;86:4295-306.
122. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, et al. Phase I and pharmacokinetic study of the ribonucleotide reductase
inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin
Oncol 2004;22:1553-63.
123. Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, et al. High-throughput screening of small molecules identifies hepcidin antagonists.
Mol Pharmacol 2013;83:681-90.
124. MacPhail AP, Mandishona EM, Bloom PD, Paterson AC, Rouault TA, et al. Measurements of iron status and survival in African iron
overload. S Afr Med J 1999;89:966-72.
125. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, et al. Dietary iron overload as a risk factor for hepatocellular
carcinoma in Black Africans. Hepatology 1998;27:1563-6.
126. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loréal O, et al. Increased liver iron stores in patients with hepatocellular carcinoma
developed on a noncirrhotic liver. Hepatology 1995;22:446-50.
127. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010;16:3603-15.